Details for: SEROQUEL XR
Company: ASTRAZENECA CANADA INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02300184 | SEROQUEL XR | QUETIAPINE (QUETIAPINE FUMARATE) | 50 MG | TABLET (EXTENDED-RELEASE) | ORAL |
| 02321513 | SEROQUEL XR | QUETIAPINE (QUETIAPINE FUMARATE) | 150 MG | TABLET (EXTENDED-RELEASE) | ORAL |
| 02300192 | SEROQUEL XR | QUETIAPINE (QUETIAPINE FUMARATE) | 200 MG | TABLET (EXTENDED-RELEASE) | ORAL |
| 02300206 | SEROQUEL XR | QUETIAPINE (QUETIAPINE FUMARATE) | 300 MG | TABLET (EXTENDED-RELEASE) | ORAL |
| 02300214 | SEROQUEL XR | QUETIAPINE (QUETIAPINE FUMARATE) | 400 MG | TABLET (EXTENDED-RELEASE) | ORAL |
Summary Reports
Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Sleep Apnoea
Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Urinary Retention
Summary Safety Review - Atypical Antipsychotics - Liver failure
Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of sleep walking and sleep-related eating disorder
Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Summary Safety Review - Atypical antipsychotics - Assessing the Potential Risk of Urinary Retention
Summary Safety Review - Atypical Antipsychotics - Liver failure
Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of sleep walking and sleep-related eating disorder
Summary Safety Review - Atypical antipsychotics - Assessing the potential risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.